These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22144412)

  • 1. Australians must have their children fully immunised to receive benefit.
    Sweet M
    BMJ; 2011 Dec; 343():d7872. PubMed ID: 22144412
    [No Abstract]   [Full Text] [Related]  

  • 2. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 3. Rubella immunization strategies in the state of São Paulo, Brazil.
    Rymkiewicz E; Zuzarte FC; de Oliveira Campos S; Pinto MI
    Bull World Health Organ; 2002; 80(3):258. PubMed ID: 11984616
    [No Abstract]   [Full Text] [Related]  

  • 4. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles immunization in Saudi Arabia: the need for change.
    Khalil MK; Al-Mazrou YY; Al-Jeffri M; Al-Ghamdy YS
    East Mediterr Health J; 2001; 7(4-5):829-34. PubMed ID: 15332786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccine coverage in children].
    Gaudelus J
    Arch Pediatr; 2010 Jun; 17(6):955-7. PubMed ID: 20654978
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunise Australia program: measles control campaign.
    Commun Dis Intell; 1998 Aug; 22(8):156. PubMed ID: 9735549
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The measles/rubella immunisation campaign in Scotland.
    Skinner R; Christie P; Cowden JM
    Health Bull (Edinb); 1996 Jan; 54(1):88-98. PubMed ID: 8820234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Australian Measles Control Campaign, 1998.
    Turnbull FM; Burgess MA; McIntyre PB; Lambert SB; Gilbert GL; Gidding HF; Escott RG; Achat HM; Hull BP; Wang H; Sam GA; Mead CL
    Bull World Health Organ; 2001; 79(9):882-8. PubMed ID: 11584738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained measles elimination in Australia and priorities for long term maintenance.
    Gidding HF; Wood J; MacIntyre CR; Kelly H; Lambert SB; Gilbert GL; McIntyre PB
    Vaccine; 2007 May; 25(18):3574-80. PubMed ID: 17300858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of epidemiological studies for progress of measles elimination].
    Mrozek-Budzyn D
    Przegl Epidemiol; 2010; 64(3):361-6. PubMed ID: 20976947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine.
    American Academy of Pediatrics. Committee on Infectious Diseases
    Pediatrics; 1998 Jan; 101(1 Pt 1):129-33. PubMed ID: 11345975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors underlying suboptimal childhood immunisation.
    Tickner S; Leman PJ; Woodcock A
    Vaccine; 2006 Nov; 24(49-50):7030-6. PubMed ID: 16890330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shortage of varicella and measles, mumps and rubella vaccines and interim recommendations from the Advisory Committee on Immunization Practices.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(9):190-1. PubMed ID: 11905460
    [No Abstract]   [Full Text] [Related]  

  • 19. Progress toward implementation of a second-dose measles immunization requirement for all schoolchildren in the United States.
    Kolasa MS; Klemperer-Johnson S; Papania MJ
    J Infect Dis; 2004 May; 189 Suppl 1():S98-103. PubMed ID: 15106097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium.
    Theeten H; Vandermeulen C; Roelants M; Hoppenbrouwers K; Depoorter AM; Van Damme P
    Acta Paediatr; 2009 Aug; 98(8):1307-12. PubMed ID: 19432835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.